Patients willing and able to provide voluntary written informed consent and to follow the protocol requirements. <br/ >Male or female patients between 18 and 60 years of age (both inclusive). <br/ >Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected â?¤5 days prior to randomization) <br/ >Patients with mild COVID-19 (non-hospitalized) and have following symptoms and signs within 3 to 5 days prior to randomization. <br/ >Patients having mild COVID-19 with a score of 2 or 3 on the 10-point ordinal scale of clinical status <br/ >Patients who are able to consume oral medications. <br/ >Males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: <br/ >Females who are not pregnant or breastfeeding <br/ >

Patients willing and able to provide voluntary written informed consent and to follow the protocol requirements. <br/ >Male or female patients between 18 and 60 years of age (both inclusive). <br/ >Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected â?¤5 days prior to randomization) <br/ >Patients with mild COVID-19 (non-hospitalized) and have following symptoms and signs within 3 to 5 days prior to randomization. <br/ >Patients having mild COVID-19 with a score of 2 or 3 on the 10-point ordinal scale of clinical status <br/ >Patients who are able to consume oral medications. <br/ >Males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: <br/ >Females who are not pregnant or breastfeeding <br/ >

Patients willing and able to provide voluntary written informed consent and to follow the protocol requirements. <br/ >Male or female patients between 18 and 60 years of age (both inclusive). <br/ >Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected â?¤5 days prior to randomization) <br/ >Patients with mild COVID-19 (non-hospitalized) and have following symptoms and signs within 3 to 5 days prior to randomization. <br/ >Patients having mild COVID-19 with a score of 2 or 3 on the 10-point ordinal scale of clinical status <br/ >Patients who are able to consume oral medications. <br/ >Males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: <br/ >Females who are not pregnant or breastfeeding <br/ >

Patients willing and able to provide voluntary written informed consent and to follow the protocol requirements. <br/ >Male or female patients between 18 and 60 years of age (both inclusive). <br/ >Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected â?¤5 days prior to randomization) <br/ >Patients with mild COVID-19 (non-hospitalized) and have following symptoms and signs within 3 to 5 days prior to randomization. <br/ >Patients having mild COVID-19 with a score of 2 or 3 on the 10-point ordinal scale of clinical status <br/ >Patients who are able to consume oral medications. <br/ >Males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: <br/ >Females who are not pregnant or breastfeeding <br/ >